2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W747072
    3-Sulfo-taurocholic Acid Disodium Salt 71781-33-4 99.9%
    3-Sulfo-taurocholic Acid Disodium Salt (3-Sulfocholyl Taurine; TCA3S) is a metabolite of the conjugated bile acid taurocholic acid. Plasma levels of 3-Sulfo-taurocholic Acid Disodium Salt are elevated in wild-type and Sortilin 1 (Sort1) knockout mice at 6 hours following bile duct ligation (BDL) and are further elevated in Sort1 knockout mice at 24 hours post-BDL.
    3-Sulfo-taurocholic Acid Disodium Salt
  • HY-100656AS
    Desmethyl cariprazine-d8 1308278-85-4 99.93%
    Desmethyl cariprazine-d8 is the deuterium labeled Desmethyl cariprazine (HY-100656). Desmethyl cariprazine is a major active metabolite of cariprazine, with activities at human dopamine receptors and serotonin receptors, showing a pEC50 of 8.90 at human D2 receptors, a pEC50 of 8.09 at D3 receptors, and a pEC50 of 6.28 at 5-HT1A receptors. Desmethyl cariprazine inhibits forskolin-induced cAMP production at D2, D3 and 5-HT1A receptors, and suppresses serotonin-induced Ca2+ release at 5-HT2B receptors. Desmethyl cariprazine is applicable to research related to schizophrenia, bipolar disorder type I and bipolar disorder.
    Desmethyl cariprazine-d8
  • HY-B0176AS1
    (±)-cis-Sertraline-d3 hydrochloride 1217741-83-7 99.54%
    (±)-cis-Sertraline-d3 (hydrochloride) is the deuterium labeled Sertraline hydrochloride. Sertraline hydrochloride is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. Sertraline hydrochloride is researched for a number of diseases, such as major depressive disorder and obsessive.
    (±)-cis-Sertraline-d3 hydrochloride
  • HY-W012998R
    2,3-Pentanedione (Standard) 600-14-6 99.07%
    2,3-Pentanedione (Standard) is the analytical standard of 2,3-Pentanedione. This product is intended for research and analytical applications. 2,3-Pentanedione is a common constituent of synthetic flavorings and is used to impart a butter, strawberry, caramel, fruit, rum, or cheese flavor in beverages, ice cream, candy, baked goods, gelatins, and puddings. 2,3-Pentanedione also occurs naturally as a fermentation product in beer, wine, and yogurt and is releasedduring roasting of coffee beans.
    2,3-Pentanedione (Standard)
  • HY-W015882S
    4-Methylpentanoic acid-d12 116287-57-1 99.25%
    4-Methylpentanoic acid-d12 (Isocaproic Acid-d12) is the deuterium labeled 4-Methylpentanoic acid. 4-Methylpentanoic acid is a short-chain fatty acid and a metabolite of 20 α-hydroxycholesterol (HY-12316) that can be detected in feces. The concentration of 4-Methylpentanoic acid is closely associated with several diseases, such as depression. 4-Methylpentanoic acid is also applicable to studies on cholesterol metabolism.
    4-Methylpentanoic acid-d12
  • HY-W019870R
    Glufosinate ammonium (Standard) 77182-82-2 99.93%
    Glufosinate (ammonium) (Standard) is the analytical standard of Glufosinate (ammonium). This product is intended for research and analytical applications. Glufosinate ammonium, a phosphinic acid analogue of glutamic acid, is an herbicide which is converted by plant cells into PT (L-phosphinothricin). Glufosinate ammonium exerts neurotoxic activity.
    Glufosinate ammonium (Standard)
  • HY-W015882S1
    4-Methylpentanoic acid-d11 344298-98-2 99.28%
    4-Methylpentanoic acid-d11 (Isocaproic Acid-d11) is the deuterium labeled 4-Methylpentanoic acid. 4-Methylpentanoic acid is a short-chain fatty acid and a metabolite of 20 α-hydroxycholesterol (HY-12316) that can be detected in feces. The concentration of 4-Methylpentanoic acid is closely associated with several diseases, such as depression. 4-Methylpentanoic acid is also applicable to studies on cholesterol metabolism.
    4-Methylpentanoic acid-d11
  • HY-A0040
    Talipexole 101626-70-4 99.75%
    Talipexole (B-HT920) is a dopamine agonist that has been proposed as an antiparkinsonian agent.
    Talipexole
  • HY-131979
    TP-040 2757254-99-0 98.59%
    TP-040 (O-GlcNAcase-IN-1), a chemical probe, is a potent and novel OGA inhibitor with an IC50 value of 46 nM.
    TP-040
  • HY-19489S
    (±)-Levomepromazine-d6 1189805-51-3 ≥98.0%
    (±)-Levomepromazine-d6 ((±)-Methotrimeprazine-d6) is the deuterium labeled (±)-Levomepromazine (HY-19489). (±)-Levomepromazine ((±)-Methotrimeprazine) is the racemate of Levomepromazine (HY-B1693).
    (±)-Levomepromazine-d6
  • HY-12761
    A-836339 959746-77-1 99.84%
    A-836339 is a selective CB2 receptor agonist, with Ki values of 0.4 nM and 0.8 nM in humans and rats, respectively. A-836339 exhibits multiple effects such as analgesia, gastric protection, anti-inflammation, and antioxidant activity. A-836339 produces antinociceptive and analgesic activities by activating CB2 receptors in the dorsal root ganglia and spinal cord. A-836339 can also exert gastric protective effects through anti-inflammatory mechanisms (reducing TNF-α and IL-1β) and antioxidant mechanisms (enhancing the activities of CAT and SOD, and reducing H2O2). Radioactively labeled A-836339 can serve as a CB2-specific radioligand for autoradiography and PET imaging. A-836339 can be used in research on inflammatory pain, neuropathic pain, gastric ulcers, cerebral ischemia, etc.
    A-836339
  • HY-16617
    Auglurant 1396337-04-4 99.34%
    Auglurant (VU0424238) is a novel and selective mGlu5 antagonist with an IC50 value of 11 nM (rat) and an IC50 value of 14 nM (human). Auglurant (VU0424238) has an acceptable CNS penetration.
    Auglurant
  • HY-101183
    THK5351 1707147-26-9 98.95%
    THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.
    THK5351
  • HY-101924
    AVN-492 1220646-23-0 99.30%
    AVN-492 is a very specific and highly-selective antagonist with picomolar affinity to 5-HT6R (Ki=91 pM).
    AVN-492
  • HY-103423
    PAOPA 114200-31-6 98.09%
    PAOPA, an analog of L-proline-l-leucine-glycine amide (PLG) peptide, is an allosteric modulator of Dopamine D2 Receptor. PAOPA can effectively reduce behavioral abnormalities in rodent models of schizophrenia. PAOPA increases the high affinity dopamine D2 receptor and promotes its binding to agonists.
    PAOPA
  • HY-106582
    Sobuzoxane 98631-95-9 98.05%
    Sobuzoxane (MST-16) is an orally active topoisomerase II inhibitor. Sobuzoxane causes irreversible inhibition of cell division. Sobuzoxane can be used in the study of non-Hodgkin's lymphoma that is resistant to conventional chemotherapy or has recurred.
    Sobuzoxane
  • HY-108337
    GNE-0723 1883518-31-7 99.91%
    GNE-0723 is a brain permeable positive allosteric modulator of NMDAR, with an EC50 of 21 nM for GluN2A, 7.4 and 6.2 μM for GluN2C and GluN2D, respectively.
    GNE-0723
  • HY-109131
    Foscarbidopa 1907685-81-7
    Foscarbidopa (ABBV-951; Carbidopa 4′-monophosphate) is an inhibitory prodrug targeting peripheral aromatic L-amino acid decarboxylase. Foscarbidopa is hydrolyzed into Carbidopa (HY-B0311) by phosphatases in vivo to suppress peripheral metabolism of levodopa and elevate brain delivery of levodopa. Foscarbidopa can be used for the research of Parkinson’s disease and advanced Parkinson’s disease.
    Foscarbidopa
  • HY-114403
    VU6012962 2313526-86-0 99.92%
    VU6012962 is an orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 negative allosteric modulator (mGlu7 NAM) with an IC50 of 347 nM.
    VU6012962
  • HY-114423
    p38α inhibitor 1 1034189-82-6 98.91%
    p38α inhibitor 1 (Arry-797) is a p38α inhibitor. p38α inhibitor 1 is applicable to research related to diseases including Alzheimer's disease and inflammatory dilated cardiomyopathy.
    p38α inhibitor 1
Cat. No. Product Name / Synonyms Application Reactivity